These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 25628464)

  • 21. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria.
    Curtis SL; Roberts NB; Ranganath LR
    Clin Biochem; 2014 May; 47(7-8):640-7. PubMed ID: 24373924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of alkaptonuria patients: single center experience.
    Bozaci AE; Yazici H; Canda E; Uçar SK; Guvenc MS; Berdeli A; Habif S; Coker M
    J Pediatr Endocrinol Metab; 2022 Jul; 35(7):913-923. PubMed ID: 35671204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R
    Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    J Inherit Metab Dis; 2021 May; 44(3):666-676. PubMed ID: 33452825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
    Sundberg J; Wibrand F; Lund AM; Christensen M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history of alkaptonuria revisited: analyses based on scoring systems.
    Ranganath LR; Cox TF
    J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.
    Mistry JB; Jackson DJ; Bukhari M; Taylor AM
    Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
    Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.
    Herebian D; Spiekerkötter U; Lamshöft M; Thimm E; Laryea M; Mayatepek E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(14-15):1453-9. PubMed ID: 19345648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous detection of diagnostic biomarkers of alkaptonuria, ornithine carbamoyltransferase deficiency, and neuroblastoma disease by high-performance liquid chromatography/tandem mass spectrometry.
    Hsu WY; Chen CM; Tsai FJ; Lai CC
    Clin Chim Acta; 2013 May; 420():140-5. PubMed ID: 23085206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
    Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitation of homogentisic acid in normal human plasma.
    Deutsch JC; Santhosh-Kumar CR
    J Chromatogr B Biomed Appl; 1996 Feb; 677(1):147-51. PubMed ID: 8925087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.
    Norman BP; Davison AS; Ross GA; Milan AM; Hughes AT; Sutherland H; Jarvis JC; Roberts NB; Gallagher JA; Ranganath LR
    Clin Chem; 2019 Apr; 65(4):530-539. PubMed ID: 30782595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A metabolic cause of spinal deformity.
    Effelsberg NM; Hügle T; Walker UA
    Metabolism; 2010 Jan; 59(1):140-3. PubMed ID: 19765774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alkaptonuria - Many questions answered, further challenges beckon.
    Davison AS; Hughes AT; Milan AM; Sireau N; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2020 Mar; 57(2):106-120. PubMed ID: 31529982
    [No Abstract]   [Full Text] [Related]  

  • 39. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging.
    Davison AS; Strittmatter N; Sutherland H; Hughes AT; Hughes J; Bou-Gharios G; Milan AM; Goodwin RJA; Ranganath LR; Gallagher JA
    Metabolomics; 2019 Apr; 15(5):68. PubMed ID: 31037385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.